John Thievon saves the Dey for Mylan
This article was originally published in Scrip
Mylan has appointed John Thievon president of Dey Pharma, its fully integrated specialty pharmaceutical business. Mr Thievon most recently served as president and CEO of MiddleBrook Pharmaceuticals, helping to build the business from an 18-person start-up to a 450-person organisation whose assets were acquired by Victory Pharma.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.